echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Lilly launches first antibody therapy clinical trial Gilead announces Redsewe trial results

    Lilly launches first antibody therapy clinical trial Gilead announces Redsewe trial results

    • Last Update: 2020-06-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    Lilly announced today that it has completed the first patient administration in Phase 1 clinical trial sitaqs with The New Crown Virus neutralizing antibody LY-CoV555, a joint development with AbCelleraThis is the world's first human clinical trial of a potential antibody therapy for COVID-19, according to the press releaseLY-CoV5555 is a powerful neutralizing antibody that targets the neo-coronavirus's synaptic protein, which is designed to block the process by which the new coronavirus enters the cellThe antibody was developed separately from blood samples from the first U.SCOVID-19 patientsAfter the initial discovery of the antibody, Lilly scientists quickly developed the antibody therapy in just three monthsclinical trial called J2W-MC-PYAA is a randomized, two-blind, placebo-controlled Phase 1 clinical trial designed to study the safety, tolerance, pharmacokinetics (PK) and pharmacodynamics (PD) of LY-CoV555 in patients hospitalized with COVID-19The results of the trial are expected to be available by the end of JuneIf Phase 1 studies show safe use of antibodies, Lilly expects to move on to the next phase of testing the effectiveness of LY-CoV5555 in non-hospitalized COVID-19 patientsThe company also plans to study the drug in a preventive environment, focusing on vulnerable patients who have historically been not the best candidates for the vaccine" antibody therapies such as LY-CoV555 may have dual potential for the prevention and treatment of COVID-19 and may be particularly important for those most affected by the disease, such as the elderly and those with compromised immune systems." DrDaniel Skovronsky, Chief Scientific Officer of Lilly and President of Lilly Research Laboratory, said, "While we are studying safety and efficacy, we are also starting to mass produce this potential therapy." If LY-CoV555 becomes part of THE NEAR-term SOLUTION for COVID-19, we hope to make it available to patients as soon as possible, with the goal of obtaining hundreds of thousands of doses of the drug by the end of the yearLilly,, also partnered with Junshi Bio to jointly develop neutralizing antibodies targeting the new coronavirusRecently, the two sides jointly developed candidate antibodies in the rhesus monkey animal experiment to confirm its prevention and treatment potentialBoth sides plan to advance clinical applications for antibodies in the second quarterLilly plans to test a variety of neo-coronavirus neutralizing antibodies as monopills, or as antibody cocktail therapy, to treat the role of PATIENTs with COVID-19 Gilead Sciences announces the results of Redseve's treatment of patients with moderate new coronapneumonia
    today, Gilead Sciences announced the results of clinical trials in the treatment of patients hospitalized with moderate new coronary pneumonia, the antiviral drug remdesivir In this open label phase 3 clinical trial, the 5-day course of Redsewe combined standard care increased the patient's likelihood of clinical improvement by 65% on the 11th day of treatment (OR s 1.65, 95% CI, 1.09-2.48, p-0.017) Redsewe's 10-day course of treatment also provides benefits for clinical improvement compared to standard treatment, but is not statistically significant The company plans to submit all the data to a peer-reviewed journal in the coming weeks comes after redsee has published data on several Phase 3 clinical trials for the treatment of severe new coronary pneumonia The difference in this trial is the treatment of patients with moderate neo-coronary pneumonia, defined as the lack of mechanical ventilation and the oxygen saturation of more than 94% of breathing air, although diagnosed with neo-coronary pneumonia and hospitalized for treatment They were randomly treated at a rate of 1:1 or 1 for Aedessiwe's 5-day or 10-day course of treatment, or standard care The primary endpoint was the clinical status assessed using a 7-level score on the 11th day after treatment The 7-level score ranged from discharge to increased oxygen and ventilation support levels to death trial results showed that the proportion of patients who achieved clinical improvement in the 5-day treatment group increased significantly on the 11th day after treatment compared to the standard care group In addition, the number of clinical deterioration or deaths in patients treated with Redsiwe decreased compared to the standard care group, but did not achieve statistically significant "We now have several randomized, controlled clinical trials that have shown that Redsewe improved clinical outcomes when treating different patient types," Today's results show that the five-day course of remdesivir offers greater clinical improvements than standard treatment when treating moderate disease Dr Merdad Parsey, Chief Medical Officer of Gilead Sciences, said: "The additional data we have today will further guide our research, including assessing the effectiveness of therapies at an earlier stage of the disease, combining other therapies with treating the most critically ill patients, and paediatric research and development of alternative dosage forms original title: COVID-19 Research and Development Dynamics Lilly launches world's first antibody therapy clinical trial, Gilead announces results of Redsewe treatment trial for moderate patients
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.